AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-22. (canceled)

- 23. (currently amended) A method for the enhancement of cognitive function and <u>alleviation of mental fatigue</u>, said method comprising: administering, to a subject in need thereof, *Ginkgo* complexed with a <u>phopholipid phospholipid</u> containing 10 to 50% of phosphatidylserine.
- 24. (previously presented) The method according to claim 23, wherein the phospholipid contains from 20 to 40% of phosphatidylserine.
- 25. (currently amended) The method according to claim 23, wherein the phospholipid contains 20% of phospatidylserine phosphatidylserine.
- 26. (previously presented) The method according to claim 23, wherein the *Ginkgo* is derived from the plant *Ginkgo biloba*, extracts thereof and/or one or more principal active substances thereof.

- 27. (previously presented) The method according to claim 26, wherein one of the principal active substances is bilobalide.
- 28. (previously presented) The method according to claim 26, wherein the *Ginkgo* extract contains at least about 20% *Ginkgo* flavone glycosides and about 2 to about 10% terpene lactones.
- 29. (previously presented) The method according to claim 23, wherein the ratio between *Ginkgo* and the phosphatidylserine in the complex is about 1:3.
- 30. (previously presented) The method according to claim 23, wherein the Ginkgo phospholipid complex is in a medicament or a dietary supplement that is administered in the form of tablets, granules, powders, capsules, syrups, solutions, suspensions, dragees, gels, injections or drops.
- 31. (previously presented) The method according to claim 23, wherein the Ginkgo phospholipid complex is in a medicament or a dietary supplement and is formulated for oral administration.
- 32. (previously presented) The method according to claim 23, wherein the *Ginkgo* phosphatidylserine complex is in a medicament or a dietary supplement that is administered in an

amount of about 20 to about 240 mg per day, or in an amount of about 60 to about 120 mg per day.

- 33. (previously presented) The method according to claim 23, wherein the Ginkgo phospholipid complex is in a medicament or a dietary supplement, and further contains a pharmaceutically acceptable amount of at least one additive selected from the group consisting of minerals, vitamins, sweeteners, flavors, pharmaceutically acceptable carriers, auxiliary and binder agents, excipients and mixtures thereof.
- 34. (previously presented) The method according to claim 33, wherein the additive is selected from vitamins, minerals and mixtures thereof, and/or is selected from calcium, fluorine, phosphorus, copper, potassium, manganese, magnesium selenium, zinc and iron, Vitamin A, Vitamins B1, B2 and B12, Vitamin C, Vitamin D2, nicotinamide, calcium pantotenate, rutoside and Vitamin E.
- 35. (currently amended) A method for the enhancement of cognitive function and <u>alleviation of mental fatigue</u> by improving the speed of memory and memory quality, by counteracting cognitive fatigue in normal, healthy persons or by preventing deterioration of the speed of memory in people with decreased cognitive functions, said method comprising administering, to a

subject in need thereof, an effective amount of a *Ginkgo* complexed with phosphatidylserine.

- **36.** (previously presented) A method for the treatment and prevention of a disease related with the reduction of cognitive function and mental fatigue, said method comprising administering, to a subject in need thereof, an effective amount of a *Ginkgo* complexed with phosphatidylserine.
- 37. (previously presented) The method according to claim 36, wherein the disease is Dementia.
- 38. (previously presented) The method according to claim 37, wherein the disease is Alzheimer's Disease.
- 39. (previously presented) The method according to claim 36, wherein the *Ginkgo* phosphatidylserine complex is in a medicament or a dietary supplement, and further contains a pharmaceutically acceptable amount of at least one additive selected from the group consisting of vitamins, minerals, sweeteners, flavors, pharmaceutically acceptable carriers, auxiliary and binder agents, excipients and mixtures thereof.
- 40. (previously presented) The method according to claim 36, further comprising administering a pharmaceutical compound

used for the treatment and prevention of the disease to be treated related with the reduction of cognitive function and mental fatigue.

- 41. (previously presented) The method according to claim 40, wherein the pharmaceutical compound is an acetylcholinesterase inhibitor.
- 42. (currently amended) The method according to claim 40, further comprising administering complexed grape seed extract, as an additionally active compound that is complexed grape seed extract.
- **43.** (withdrawn) A pharmaceutical or dietary composition comprising *Ginkgo* complex and at least one vitamin and a pharmaceutically or dietarily acceptable carrier.
- **44.** (withdrawn) A complex of an extract of *Ginkgo* with a phosphatidylserine of formula

wherein

R and R^1 each independently represent an acyl moiety selected from the fatty acids consisting of palmitic acid, oleic acid, linoleic acid, stearic acid.

- 45. (withdrawn) A complex according to claim 44, which comprises from 15 to 25% of saturated fatty acids, from 5 to 15% of mono-unsaturated fatty acids and from 60 to 80% of polyunsaturated fatty acids, based on the total acids.
- **46. (previously presented)** The method of claim 23, wherein the ratio between Ginkgo and the phosphatidylserine is 0.5-1:2-5.